ScienceDirect - The Lancet Neurology : A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
Links shared publicly online about this topic.
- 361total visits
ScienceDirect - The Lancet Neurology : A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
ScienceDirect - The Lancet Neurology : A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
View full resource at sciencedirect.com
Tags: Neurology, Parkinson's Disease, Disease and Condition, Clinical Trial, disease
Most Recently Shared on April 16, 2011 at 9:01 am By:
Analysis of the results of the ADAGIO study will inform us of future clinical trial design. http://t.co/NEyDoKq
Advertisement
